Literature DB >> 12878531

Comparison of two methods and three end points in determination of in vitro activity of micafungin against Aspergillus spp.

Sevtap Arikan1, Pinar Yurdakul, Gulsen Hascelik.   

Abstract

We investigated the in vitro activity of micafungin against clinical Aspergillus isolates (n = 37) (Aspergillusfumigatus [n = 21], Aspergillusflavus [n = 14], and Aspergillus niger [n = 2]) by using NCCLS M38A microdilution and an investigational disk diffusion assay. Microdilution assay results were evaluated by using the end points of a MIC-2 (measured in micrograms per milliliter) and minimum effective concentration (MEC, measured in micrograms per milliliter; the lowest concentration of micafungin that produces short and aberrant hyphal branchings microscopically). Disk diffusion results were interpreted by measuring the zone(s) of inhibition (ZOI, measured in millimeters). Micafungin proved to be similarly active against all Aspergillus species tested. At 24 h, MIC-2s and MECs were identical. At 48 h, however, MIC-2s increased unpredictably, leading to the loss of a consistent correlation between the two end points. MECs and ZOI remained consistent and correlated at both reading times, suggesting their use as relevant end points in susceptibility testing of micafungin against Aspergillus: All Aspergillus isolates yielded intrazonal growth on disk diffusion agar plates. The intrazonal colonies contained short, aberrant hyphal branchings microscopically. The in vivo significance of these findings remains to be further investigated.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12878531      PMCID: PMC166107          DOI: 10.1128/AAC.47.8.2640-2643.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

Review 1.  New targets and delivery systems for antifungal therapy.

Authors:  T J Walsh; M A Viviani; E Arathoon; C Chiou; M Ghannoum; A H Groll; F C Odds
Journal:  Med Mycol       Date:  2000       Impact factor: 4.076

2.  Comparative evaluation of disk diffusion with microdilution assay in susceptibility testing of caspofungin against Aspergillus and Fusarium isolates.

Authors:  Sevtap Arikan; Victor Paetznick; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

3.  New agents for the treatment of systemic fungal infections--current status.

Authors:  Sevtap Arikan; John H Rex
Journal:  Expert Opin Emerg Drugs       Date:  2002-05       Impact factor: 4.191

4.  In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp.

Authors:  Sevtap Arikan; Mario Lozano-Chiu; Victor Paetznick; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

5.  In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide.

Authors:  H Mikamo; Y Sato; T Tamaya
Journal:  J Antimicrob Chemother       Date:  2000-09       Impact factor: 5.790

6.  Effect of the growth medium on the in vitro antifungal activity of micafungin (FK-463) against clinical isolates of Candida dubliniensis.

Authors:  F M Müller; O Kurzai; J Hacker; M Frosch; F Mühlschlegel
Journal:  J Antimicrob Chemother       Date:  2001-11       Impact factor: 5.790

7.  In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates.

Authors:  S Arikan; M Lozano-Chiu; V Paetznick; J H Rex
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

8.  In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi.

Authors:  S Tawara; F Ikeda; K Maki; Y Morishita; K Otomo; N Teratani; T Goto; M Tomishima; H Ohki; A Yamada; K Kawabata; H Takasugi; K Sakane; H Tanaka; F Matsumoto; S Kuwahara
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

9.  Synergy, pharmacodynamics, and time-sequenced ultrastructural changes of the interaction between nikkomycin Z and the echinocandin FK463 against Aspergillus fumigatus.

Authors:  C C Chiou; N Mavrogiorgos; E Tillem; R Hector; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

Review 10.  Update on antifungals targeted to the cell wall: focus on beta-1,3-glucan synthase inhibitors.

Authors:  N H Georgopapadakou
Journal:  Expert Opin Investig Drugs       Date:  2001-02       Impact factor: 6.206

View more
  10 in total

1.  Development and multicentre validation of an agar-based screening method for echinocandin susceptibility testing of Aspergillus species.

Authors:  Joseph Meletiadis; Maria Siopi; Lamprini Kanioura; Karin Meinike Jørgensen; David S Perlin; Johan W Mouton; Maiken Cavling Arendrup
Journal:  J Antimicrob Chemother       Date:  2019-08-01       Impact factor: 5.790

2.  Overexpression of Candida albicans CDR1, CDR2, or MDR1 does not produce significant changes in echinocandin susceptibility.

Authors:  K Niimi; K Maki; F Ikeda; A R Holmes; E Lamping; M Niimi; B C Monk; R D Cannon
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

3.  In vitro antifungal activity of micafungin and caspofungin against dermatophytes isolated from China.

Authors:  Ying-qiu Bao; Zhe Wan; Ruo-yu Li
Journal:  Mycopathologia       Date:  2012-09-17       Impact factor: 2.574

4.  Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.

Authors:  Manuel Cuenca-Estrella; Alicia Gomez-Lopez; Emilia Mellado; Araceli Monzon; Maria J Buitrago; Juan L Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2009-02-17       Impact factor: 5.191

5.  Effect of caspofungin on metabolite profiles of Aspergillus species determined by nuclear magnetic resonance spectroscopy.

Authors:  R Plummer; J Bodkin; D Power; N Pantarat; W A Bubb; P W Kuchel; T C Sorrell
Journal:  Antimicrob Agents Chemother       Date:  2007-09-04       Impact factor: 5.191

6.  Comparison of Disc Diffusion, Etest, and a Modified CLSI Broth Microdilution Method for In Vitro Susceptibility Testing of Itraconazole, Posaconazole, and Voriconazole against Madurella mycetomatis.

Authors:  Bertrand Nyuykonge; Lukas van Amelsvoort; Kimberly Eadie; Ahmed H Fahal; Annelies Verbon; Wendy van de Sande
Journal:  Antimicrob Agents Chemother       Date:  2021-08-17       Impact factor: 5.191

7.  Anidulafungin and its role in candida infections.

Authors:  Diane M Cappelletty; Rose Jung
Journal:  Infect Drug Resist       Date:  2009-06-30       Impact factor: 4.003

8.  Micafungin in the treatment of invasive candidiasis and invasive aspergillosis.

Authors:  Nathan P Wiederhold; Jason M Cota; Christopher R Frei
Journal:  Infect Drug Resist       Date:  2009-01-12       Impact factor: 4.003

Review 9.  Methods for in vitro evaluating antimicrobial activity: A review.

Authors:  Mounyr Balouiri; Moulay Sadiki; Saad Koraichi Ibnsouda
Journal:  J Pharm Anal       Date:  2015-12-02

10.  Review of the pharmacology and clinical studies of micafungin.

Authors:  Alison M Bormann; Vicki A Morrison
Journal:  Drug Des Devel Ther       Date:  2009-12-29       Impact factor: 4.162

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.